Celltrion Receives Korean MFDS Approval to Initiate Phase I Trial of COVID-19 Antiviral Antibody Treatment Candidate, CT-P59, in Patients
Celltrion Group announced today that the Korean Ministry of Food and Drug Safety (MFDS) has approved the company’s Investigational New Drug (IND) application for a Phase I clinical trial of CT-P59, a COVID-19 antiviral antibody treatment candidate. Celltrion has initiated enrolment of patients with mild symptoms of SARS-CoV-2 infection and the clinical trial is set to evaluate the safety, tolerability, efficacy, pharmacokinetics and immunogenicity of CT-P59.
Celltrion anticipates global pivotal study results from the Phase II and III trials in patients with mild symptoms, the Phase III trial in patients with moderate-to-severe COVID-19, and the prevention clinical trial, by the end of the year. Celltrion plans to enrol people that are in close contact with COVID-19 patients and those with no symptoms as part of a prevention clinical trial to evaluate whether CT-P59 can elicit a neutralising antibody response to prevent the virus from infecting human cells.
“We have initiated an in-human global Phase I clinical trial of CT-P59 in mild COVID-19 patients and we plan to conduct further global Phase II and III trials in this patient group. In addition, Celltrion plans to combine Phase II and III trials in patients with moderate-to-severe COVID-19 with the prevention clinical trials.” said Dr. Sang Joon Lee, Senior Executive Vice President of Celltrion. “We are extremely encouraged by the consistent progress we are making in preparation for our CT-P59 clinical trials in various settings, and we remain on track to reach our upcoming milestones.”
In July, Celltrion initiated a Phase I trial of CT-P59 in the UK following the approval of the clinical trial authorisation (CTA) application from the UK Medicines and Healthcare products Regulatory Agency (MHRA). Celltrion has also completed an infusion and initial safety assessment for the Phase I study in healthy volunteers in Korea and the study is set for completion by Q3 this year as originally planned.
- ENDS -
Notes to Editors:
About Celltrion Healthcare
Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines. Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 110 different countries. For more information please visit: https://www.celltrionhealthcare.com/en-us
About COVID-191,2
Coronaviruses (CoV) are a family of viruses that lead to illnesses from the common cold to severe diseases. Novel coronavirus SARS-CoV-2 is responsible for the disease COVID-19, this new strain, discovered in 2019, is behind the ongoing pandemic outbreak.
The most common signs of COVID-19 include fever, dry cough and tiredness; however, people may also experience other symptoms including shortness of breath and breathing difficulties. Most people infected with the virus will exhibit mild to moderate symptoms however older people, and those with existing underlying conditions such as cardiovascular disease and diabetes are more likely to develop a more severe form of COVID-19.
Please find up to date information about the outbreak via the World Health Organization at https://www.who.int/health-topics/coronavirus#tab=tab_1
FORWARD LOOKING STATEMENT
Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion/Celltrion Healthcare that may constitute forward-looking statements, under pertinent securities laws.
These statements may be identified by words such as “prepares”, “hopes to”, “upcoming”, ”plans to”, “aims to”, “to be launched”, “is preparing, “once gained”, “could”, “with the aim of”, “may”, “once identified”, “will”, “working towards”, “is due”, “become available”, “has potential to”, the negative of these words or such other variations thereon or comparable terminology.
In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion/Celltrion Healthcare's management, of which many are beyond its control.
Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.
Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.
Although forward-looking statements contained in this presentation are based upon what management of Celltrion/Celltrion Healthcare believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Celltrion/Celltrion Healthcare undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.
References
1 Coronavirus. World Health Organization. Available at: https://www.who.int/health-topics/coronavirus#tab=tab_1 Last accessed: August 2020
2 Coronaviruses. National Institute of Allergy and Infectious Diseases. Available at: https://www.niaid.nih.gov/diseases-conditions/coronaviruses Last accessed: August 2020
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200826005516/en/
Contact information
Zuzanna Grzeskiewicz
zgrzeskiewicz@hanovercomms.com
+44 (0) 7506 339043
Sophia Eminson
seminson@hanovercomms.com
+44 (0) 7751 116252
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cardo AI Powers Multitude Bank’s Asset-Based Lending15.9.2025 09:21:00 EEST | Press release
Cardo AI, a leading technology platform for asset-based finance and private credit, today announced a strategic partnership with Multitude Bank p.l.c., a subsidiary of the listed Multitude AG. The collaboration will use Cardo AI’s platform to automate and streamline Multitude Bank’s asset-based lending (ABL) operations, enhancing efficiency and transparency in funding for small and medium-sized enterprises (SMEs). “Technology is the key to accelerating growth in asset-based credit,” said Altin Kadareja, Co-Founder & CEO of Cardo AI. “By automating and streamlining critical operations, our platform helps institutions like Multitude enhance the efficiency of their ABL businesses and provide faster, more flexible funding solutions to SMEs.” “Our clients expect both speed and reliability,” said Alain Nydegger, CEO of Wholesale Banking at Multitude Group. “By working with innovative technology partners, we can scale our asset-based lending operations more efficiently. Consolidating our ABL
Curatis: Double-Digit Growth in Core Business and Development Milestone Achieved for C-PTBE-0115.9.2025 08:00:00 EEST | Press release
Curatis Holding AG (SIX:CURN) reports revenues of CHF 5.2m for H1 2025, a like for like yoy growth of 14% vs 6 months of revenues of Curatis AG in 2024. In addition, Curatis was able to sign a significant partnership with Phoenix Labs, Ireland, adding 4 products that generated approximately CHF 5m of revenues in 2024. The loss for the period amounted to CHF -1.2m, mainly driven by increased development expenses for C-PTBE-01 (corticorelin). Cash flow amounted to CHF -1.0m. As planned, Curatis held a Type B meeting with the US Food and Drug Administration (FDA) on 9 September 2025. Business development and finances Product sales in the first half of the year amounted to CHF 5.0m and services revenues to CHF 0.2m. Curatis AG was able to increase the sales of its distribution business from CHF 4.6m (H1 2024) to CHF 5.2m (H1 2025) in the entire 6 months due to strong organic growth of the existing portfolio and new products, which corresponds to a growth of 14%. The loss for the period amo
ARAMIS Global Ambassador, Dwyane Wade, Celebrates New Fragrance Launch During New York Fashion Week13.9.2025 20:13:00 EEST | Press release
Heritage men’s fragrance brand, ARAMIS, officially launched its new scent, Intuition, with global ambassador, Dwyane Wade, during New York Fashion Week. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250913048158/en/ ARAMIS Global Ambassador, Dwyane Wade, attends Brand’s NYFW Pop-Up at The High Line (Courtesy of BFA ) The celebration kicked off with an immersive pop-up on New York City’s iconic High Line, where guests explored the story behind the fragrance through scent, sound, and design. Dwyane Wade made a personal appearance at the interactive event, joined by his wife, actress Gabrielle Union. Later in the afternoon, Wade participated in an intimate conversation around personal grooming, fragrance, and modern masculinity at Bloomingdale's 59th Street. Moderated by Mike Muse, the conversation also featured Donato Smith, Wade's longtime barber, and friend. Bloomingdale’s top clients were given the opportunity to connect i
SUI Group Announces Completion of Existing $2 Million Stock Repurchase Program and Subsequent Authorization of New $50 Million Program12.9.2025 23:05:00 EEST | Press release
SUI Group Holdings Limited (“SUI Group,” “SUIG” or the “Company”) (NASDAQ: SUIG), the only publicly traded company with an official relationship with the Sui Foundation, today announced it has completed its previously authorized $2 million stock repurchase program. SUI Group is also announcing that its Board of Directors has now authorized a new stock repurchase program to acquire up to an additional $50 million of the Company’s common stock. Following the completion of its initial stock repurchase program, in which the Company repurchased approximately 318,743 shares of its common stock at an average price of $4.30 per share between September 10, 2025 and September 12, 2025, SUI Group’s new program provides the flexibility to support its Net Asset Value (“NAV”) per share by opportunistically purchasing its common stock. The Company believes that share repurchases at these levels are immediately accretive to existing stockholders and reflects its confidence in its underlying fundamenta
Allied Nations Gather to Discuss Future of Multilateral Defence Security Financing12.9.2025 18:35:00 EEST | Press release
The Defence, Security and Resilience Bank (DSRB) Development Group co-hosted an international conference in the City of London this week to discuss the creation of a new multilateral bank designed to bring capital market expertise to the frontlines of global security. The event at Mansion House, co-hosted by the Lord Mayor of London, included 72 attendees from 37 countries across the NATO alliance, the EU, and Indo-Pacific allied nations. Held on the eve of the Defence and Security Equipment International (DSEI event), the DSRB “Information Day” event also included a further 88 attendees from a wide range of institutions including the European Union, NATO, eight partner commercial banks, multiple development and central banks as well as representatives from global funds, ratings agencies, industry associations and think tanks. Notes to Editors: The DSR Bank Development Group is a non-profit working toward the establishment of the full bank alongside nation states and institutions. The
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom